Liver Diseases, Metabolic Syndrome X
Conditions
Keywords
fructose, dietary lipids, dietary proteins, hepatic steatosis, insulin resistance, Healthy humans, overweight humans, obese humans
Brief summary
The purpose of this study is to assess how the macronutrient composition of the diet effects * lipid and glucose metabolism * intrahepatic lipids * insulin sensitivity in healthy lean subjects and in subjects with a high metabolic risk (ie overweight and offsprings of patients with type 2 diabetes mellitus).
Detailed description
The study is aimed at assessing the effects of changes in total energy, sugars, lipids, and protein intake on intrahepatic lipids, plasma lipids, and hepatic and whole body insulin resistance in * lean men and women with no family history of diabetes * overweight men and women * lean men with a family history of type 2 diabetes Subjects are studied after a 6-day period of * isocaloric diet with 100% calorie requirement, of which 55% carbohydrate, 15% protein, and 30% fat) * the same isocaloric diet supplemented with 3g/kg body weight/day fructose * hypercaloric high fat diet with 130% energy requirement, of which 55% carbohydrate, 15% protein, 60% fat * hypercaloric high fat+protein diet with 145% energy requirement, of which 55% carbohydrate, 30% protein, 60% fat Measurements performed after 6 days on each diet include * intrahepatic and intramyocellular lipids (1H-MRS) * hepatic and whole body insulin sensitivity (hyperinsulinemic-euglycemic clamp) * body weight * plasma concentrations of hormones and substrates * gene expression profile in skeletal muscle (vastus lateralis) and adipose tissue (subcutaneous abdominal)
Interventions
controlled hypercaloric high fructose, high fat, or high fat/high protein diet
Sponsors
Study design
Eligibility
Inclusion criteria
* Males and females * Age 18-40 * Informed consent obtained * Subgroup with overweight (body mass index \[BMI\] \> 25) * Subgroup with family history of type 2 diabetes mellitus
Exclusion criteria
* Smokers * Alcohol intake \> 30g/day * Drug abuse * Diabetes mellitus * Any concurrent medication * Having a pacemaker * History of orthopedic surgery * History of metal foreign bodies
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| plasma triglycerides | 6 days |
| intra-hepatic lipids | 6 days |
| insulin mediated glucose disposal | 6 days |
Secondary
| Measure | Time frame |
|---|---|
| lipid oxidation | 6 days |
| plasma beta-hydroxybutyrate | 6 days |
| gene expression in skeletal muscle and adipose tissue | 6 days |
Countries
Switzerland